Clinical trial
Phase II Study of Nonsense Readthrough Compound NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy Patients (NORTH POLE DMD Study)
NCT01918384 is registered in ClinicalTrials.gov with Kobe University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Nonsense Readthrough Compound NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy Patients (NORTH POLE DMD Study)
- Lead sponsor
- Kobe University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 31, 2013
- Completion date
- October 31, 2015
- Enrollment
- 21 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.